Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058188 · ClinicalTrials.gov registry record · Phase 3
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
A Phase 3 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 53
- Enrollment target
NCT00058188 is a Phase 3 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 53 participants.
The verdict
NCT00058188, a Phase 3 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 53 participants
- Enrollment target
Study Summary
RATIONALE: Zoledronate may prevent bone loss associated with long term androgen deprivation therapy. It is not yet known whether zoledronate combined with calcium is more effective than calcium alone in preventing bone loss. PURPOSE: Randomized phase III trial to compare the effectiveness of zoledronate combined with calcium with that of calcium alone in preventing bone loss in patients with stage III or stage IV prostate cancer who have received long-term androgen deprivation therapy.
Interventions
- DRUG zoledronic acid
- DRUG calcium gluconate
- DIETARY_SUPPLEMENT cholecalciferol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2003-03 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058188
The ClinicalTrials.gov registry entry for NCT00058188 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which zoledronic acid is the first listed.
NCT00058188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00058188 about?
NCT00058188 is a clinical study titled "Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation". RATIONALE: Zoledronate may prevent bone loss associated with long term androgen deprivation therapy. It is not yet known whether zoledronate combined with calcium is more effective than calcium alone in preventing bone loss. PURPOSE: Randomized phase III trial to compare the effectiveness of zoledr...
What is the current status of trial NCT00058188?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 53 participants. The study started on 2003-03. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00058188?
The interventions under investigation include: zoledronic acid (DRUG), calcium gluconate (DRUG), cholecalciferol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00058188?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.